Annual Reports in Medicinal Chemistry book cover

Annual Reports in Medicinal Chemistry

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.

Audience
medicinal, pharmaceutical, and organic chemists

Paperback, 472 Pages

Published: October 2012

Imprint: Academic Press

ISBN: 978-0-12-396492-2

Reviews

  • This series is one of the very few annual publications which justify the title of an absolute must for the pharmacologist, chemist, or physician who is interested in the chemistry of drug development." - ENZYMOLOGIA


Contents

  • Personal Essay

    1. Reflections on Medicinal Chemistry at Merck, West Point
    2. Paul S. Anderson

    3. My Path in Seeking New Medicines
    4. Peter R. Bernstein

    5. Tales of Drug Discovery
    6. M. Ross Johnson

      I. Central Nervous System Diseases

      Section Editor: Albert J. Robichaud; Sage Therapeutics, Inc. Cambridge, Massachusetts

    7. Recent Developments in Targeting Neuroinflammation in Disease
    8. Allen T. Hopper, Brian M. Campbell, Henry Kao, Sean A. Pintchovski and Roland G. W. Staal

    9. Secretase Inhibitors and Modulators as a Disease Modifying Approach Against Alzheimer’s Disease
    10. Harrie J. M. Gijsen and François P. Bischoff

    11. mGluR2 Activators and mGluR5 Blockers Advancing in the Clinic for Major CNS Disorders
    12. Sylvain Célanire, Guillaume Duvey, Sonia Poli and Jean-Philippe Rocher

    13. NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C and GluN2D Subtypes - Recent Results and Developments
    14. Kamalesh B. Ruppa, Dalton King and Richard Olson

    15. Recent Advances in the Development of PET and SPECT Tracers for Brain Imaging
    16. Lei Zhang and Anabella Villalobos

      II. Cardiovascular and Metabolic Diseases

      Section Editor: Andy Stamford, Merck Research Laboratories, Kenilworth, New Jersey

    17. Case History: EliquisTM (Apixaban), a Potent and Selective Inhibitor of Coagulation Factor Xa for the Prevention and Treatment of Thrombotic Diseases
    18. Donald J. P. Pinto, Pancras C. Wong, Robert M. Knabb and Ruth R. R. Wexler

    19. AMPK Activation in Health and Disease
    20. Iyassu K. Sebhat and Robert W. Myers

    21. Type-2 Diabetes and Associated Co-Morbidities as an Inflammatory Syndrome
    22. Juan C. Jaen, Jay P. Powers and Tim Sullivan

    23. Beyond PPARs & Metformin: New Insulin Sensitizers for the Treatment of Type 2 Diabetes
    24. Philip A. Carpino and David Hepworth

      III. Inflammatory Pulmonary and Gastrointestinal Diseases

      Section Editor: David S. Weinstein, Bristol-Myers Squibb R&D, Princeton, New Jersey

    25. Recent Advances in the Discovery and Development of Sphingosine-1-Phosphate-1 Receptor Agonists
    26. Alaric J. Dyckman

    27. Bifunctional Compounds for the Treatment of COPD
    28. Gary Phillips and Michael Salmon

    29. Inflammatory Targets for the Treatment of Atherosclerosis
    30. Robert O. Hughes, Alessandra Bartolozzi and Hidenori Takahashi

      IV. Oncology

      Section Editor: Shelli R. McAlpine, School of Chemistry, University of New South Wales, Sydney, Australia

    31. Nanotechnology Therapeutics in Oncology - Recent Developments and Future Outlook
    32. Paul F. Richardson

    33. Small-Molecule Antagonists of Bcl-2 Family Proteins
    34. Sean P. Brown and Joshua P. Taygerly

    35. Notch Pathway Modulators as Anti-Cancer Chemotherapeutics
    36. Vibhavari Sail and M. Kyle Hadden

    37. Anaplastic Lymphoma Kinase (ALK) Inhibitors for the Treatment of ALK-Positive Cancers
    38. Kazutomo Kinoshita, Nobuhiro Oikawa and Takuo Tsukuda

      V. Infectious Diseases

      Section Editor: John Primeau, Westford, Massachusetts

    39. Recent Advances in the Discovery of Dengue Virus Inhibitors
    40. Jeremy Green, Upul Bandarage, Kate Luisi and Rene Rijnbrand

    41. Non Fluoro-Quinolone Based Inhibitors of Mycobacterial Type II Topoisomerase as Potential Therapeutic Agents for TB
    42. Pravin S. Shirude and Shahul Hameed

    43. HCV Inhibition Mediated through the Nonstructural Protein 5A (NS5A) Replication Complex
    44. Robert Hamatake, Andrew Maynard and Wieslaw M. Kazmierski

      VI. Topics in Biology

      Section Editor: John Lowe, JL3Pharma LLC, Stonington, Connecticut

    45. Antibody-Drug Conjugates for Targeted Cancer Therapy
    46. Victor S. Goldmacher, Thomas Chittenden, Ravi V. J. Chari, Yelena V. Kovtun and John M. Lambert

    47. 3D Cell Cultures: Mimicking in Vivo Tissues for Improved Predictability in Drug Discovery
    48. Indira Padmalayam and Mark J. Suto

    49. Virally Encoded G Protein-Coupled Receptors: Overlooked Therapeutic Opportunities?
    50. Nuska Tschammer

    51. Recent Advances in Wnt/b-Catenin Pathway Small Molecule Inhibitors
    52. Daniel D. Holsworth and Stefan Krauss

      VII. Topics in Drug Design and Discovery

      Section Editor: Peter R. Bernstein, PhaRmaB LLC, Rose Valley, Pennsylvania

    53. Targeted Covalent Enzyme Inhibitors
    54. Mark C. Noe and Adam M. Gilbert

    55. Drug Design Strategies for GPCR Allosteric Modulators
    56. P. Jeffrey Conn, Scott D. Kuduk and Darío Doller

    57. Progress in the Development of Non-ATP Competitive Protein Kinase Inhibitors for Oncology
    58. Campbell McInnes

      VIII. Trends

      Section Editor: Joanne Bronson, Bristol-Myers Squibb, Wallingford, Connecticut

    59. New Chemical Entities Entering Phase III Trials in 2011
    60. Gregory T. Notte

    61. To Market, To Market - 2011

      Joanne Bronson, Murali Dhar, William Ewing and Nils Lonberg

Advertisement

advert image